Wockhardt Targets ₹1,000 Crore Indian Market with New Antibiotic Foviscu
Business
C
CNBC TV18•28-01-2026, 15:28
Wockhardt Targets ₹1,000 Crore Indian Market with New Antibiotic Foviscu
- •Wockhardt's Founder Chairman, Habil F Khorakiwala, estimates a ₹1,000 crore Indian market potential for its new antibiotic, Foviscu (WCK 4282).
- •The new molecule, WCK 4282, successfully completed Phase 3 clinical trials for complicated urinary tract infections, showing comparable effectiveness to standard treatments.
- •A key advantage of Foviscu is its ability to address multi-drug resistance, making it suitable for critical infections without exacerbating resistance.
- •Wockhardt plans to file for regulatory approval with the DCGI in India soon, hoping for faster clearances under new government guidelines.
- •Initial launch will be in India, with future expansion into other emerging markets; global antibiotic Zaynich also progressing towards US and European approvals.
Why It Matters: Wockhardt aims for a significant share of the Indian market with its new, resistance-friendly antibiotic Foviscu.
✦
More like this
Loading more articles...
